How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in school
How AI is Changing the Safeguarding Landscape
March 24, 2026

This episode of “Safeguarding in Focus,” hosted by Sam Eustace, features Lucie Welch, an expert in primary education and safeguarding from Services for Education. The discussion centers on how AI is transforming the safeguarding landscape in schools, exploring both the risks and opportunities presented by this rapidly evolving technology. Key takeaways: Schools must address…

Read More
skilled trades mentorship
Why Leadership Without Humanity Is Failing Today’s Workplace
March 24, 2026

As the world faces historic labor shortages, an increase in burnout, and record-high turnover, organizations are confronting a leadership reckoning. In May 2024, Gallup found that more than 50 percent of U.S. employees were actively searching for new jobs or watching for openings. Taken together, these trends signal a clear and growing breakdown in…

Read More
Joint Commission 360
Understanding Joint Commission 360 Standards: What They Mean for SPD Teams (Part 2)
March 23, 2026

Healthcare teams today are feeling the pressure to move beyond last-minute compliance and instead build processes that work consistently every day. That shift is especially clear in sterile processing departments (SPDs), where the Joint Commission 360 model is redefining what “survey readiness” really means. With patient safety directly tied to instrument quality—and studies consistently…

Read More
teacher
Building the Next Generation of Educators Through Apprenticeship Pathways and Workforce-Aligned Training
March 23, 2026

Teacher shortages aren’t exactly a new headline—but lately, they’ve started to feel a lot more urgent. In some places, schools have gone years without enough fully trained teachers in the classroom, exposing real flaws in how we prepare and retain educators. Add in the rising cost of becoming a teacher and training models that haven’t…

Read More